Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick L Locke

Showing results (91-100 of 234) with videos related to

Pageof 24
Sort By:
Blood Advances|July 9, 2021
A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease preventionLia Perez, Hugo Fernandez, Mohamed Kharfan-Dabaja, et al.
Cancers|June 10, 2022
Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data VisualizationLaura B Oswald, Xiaoyin Li, Rodrigo Carvajal, et al.
Haematologica|April 5, 2015
Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host diseaseJoseph Pidala, Jongphil Kim, Melissa Alsina, et al.
Blood Advances|July 11, 2022
Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCLAriel Perez, Grace Johnson, Kedar Patel, et al.
Blood Advances|January 5, 2024
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortalityKai Rejeski, Yucai Wang, Doris K Hansen, et al.
Blood|April 27, 2022
Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphomaMichael D Jain, Bachisio Ziccheddu, Caroline A Coughlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2016
CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell TransplantationFrederick L Locke, Joseph Pidala, Barry Storer, et al.
Transplantation and Cellular Therapy|December 29, 2024
Real-World Patient-Reported and Neurocognitive Outcomes in the Year After Axicabtagene CiloleucelAasha I Hoogland, Xiaoyin Li, Karnav Modi, et al.
International Journal of Radiation Oncology, Biology, Physics|July 9, 2021
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell TherapyNicholas B Figura, Timothy J Robinson, Austin J Sim, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
Pageof 24

Showing results (91-100 of 234) with videos related to

Sort By:
Pageof 24
Blood Advances|July 9, 2021
A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease preventionLia Perez, Hugo Fernandez, Mohamed Kharfan-Dabaja, et al.
Cancers|June 10, 2022
Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data VisualizationLaura B Oswald, Xiaoyin Li, Rodrigo Carvajal, et al.
Haematologica|April 5, 2015
Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host diseaseJoseph Pidala, Jongphil Kim, Melissa Alsina, et al.
Blood Advances|July 11, 2022
Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCLAriel Perez, Grace Johnson, Kedar Patel, et al.
Blood Advances|January 5, 2024
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortalityKai Rejeski, Yucai Wang, Doris K Hansen, et al.
Blood|April 27, 2022
Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphomaMichael D Jain, Bachisio Ziccheddu, Caroline A Coughlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2016
CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell TransplantationFrederick L Locke, Joseph Pidala, Barry Storer, et al.
Transplantation and Cellular Therapy|December 29, 2024
Real-World Patient-Reported and Neurocognitive Outcomes in the Year After Axicabtagene CiloleucelAasha I Hoogland, Xiaoyin Li, Karnav Modi, et al.
International Journal of Radiation Oncology, Biology, Physics|July 9, 2021
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell TherapyNicholas B Figura, Timothy J Robinson, Austin J Sim, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
Pageof 24